Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia

Anne Louise Oaklander1, Zeva Daniela Herzog, Heather M Downs

  • 1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Department of Pathology (Neuropathology), Massachusetts General Hospital, Boston, MA, USA.

Pain
|June 11, 2013
PubMed

Insights

Many fibromyalgia patients may have undiagnosed small-fiber polyneuropathy (SFPN). This study found objective evidence of SFPN in 41% of fibromyalgia patients, suggesting a distinct, treatable cause for their chronic pain.

Area of Science:

  • Neurology
  • Rheumatology
  • Pathology

Background:

  • Fibromyalgia is a disabling syndrome with chronic widespread pain and diverse symptoms.
  • Lack of objective abnormalities hinders diagnosis, treatment, and cause identification for fibromyalgia.
  • Small-fiber polyneuropathy (SFPN) causes similar symptoms and is a distinct disease of small-fiber neurons with identifiable causes.

Purpose of the Study:

  • To test the hypothesis that some fibromyalgia patients have unrecognized SFPN.
  • To identify objective markers for SFPN in fibromyalgia patients.

Main Methods:

  • Analyzed SFPN symptoms, neurological exams, and markers in 27 fibromyalgia patients and 30 controls.
  • Utilized Michigan Neuropathy Screening Instrument (MNSI), Utah Early Neuropathy Scale (UENS), skin biopsies, and autonomic-function testing (AFT).

Main Results:

  • 41% of fibromyalgia patients showed SFPN-diagnostic skin biopsies, versus 3% in controls.
  • Higher MNSI and UENS scores in fibromyalgia patients (P ≤ 0.001).
  • Abnormal AFTs were equally prevalent, indicating primarily somatic SFPN.

Conclusions:

  • A significant portion of fibromyalgia patients may have undiagnosed SFPN.
  • SFPN is an objective, distinct disease that can be diagnosed and sometimes treated.
  • Identified potential causes including dysimmune and genetic factors in some patients.

Related Concept Videos

Local Anesthetics: Differential Sensitivity of Nerve Fibers01:24

Local Anesthetics: Differential Sensitivity of Nerve Fibers

Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...